2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Keywords

TrastuzumabMedicineInternal medicineHazard ratioBreast cancerOncologyClinical endpointClinical trialChemotherapyAdjuvantCancerSurgeryConfidence interval

Affiliated Institutions

Related Publications

Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

Mitch Dowsett , Marion Procter , Worta McCaskill‐Stevens +11 more

Purpose To determine whether (1) immunohistochemical (IHC) HER2 status (ie, 2+ or 3+), (2) degree of fluorescence in situ hybridization (FISH) amplification according to (2a) HE...

2009 Journal of Clinical Oncology 184 citations

Trastuzumab-Induced Hepatotoxicity: A Case Report

D. Vucicevic , Elizabeth J. Carey , Nina J. Karlin

Background: Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overe...

2013 Breast Care 4416 citations

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Harold J. Burstein , Lyndsay N. Harris , P. Kelly Marcom +15 more

Purpose: Trastuzumab-based therapy improves survival for women with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. We conducted a multicenter p...

2003 Journal of Clinical Oncology 343 citations

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Charles L. Vogel , Melody Cobleigh , Debu Tripathy +10 more

Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by ...

2002 Journal of Clinical Oncology 2948 citations

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart , Marion Procter , Brian Leyland‐Jones +29 more

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov...

2005 New England Journal of Medicine 5034 citations

Publication Info

Year: 2007
Type: article
Volume: 369
Issue: 9555
Pages: 29-36
Citations: 1503
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1503

OpenAlex

Cite This

APA Style

                            
                                
                                    Ian Smith, 
                                
                                    Marion Procter, 
                                
                                    Richard D. Gelber
                                
                                et al.
                            
                            (2007). 
                            2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. 
                            The Lancet
                            , 369
                            (9555)
                            , 29-36.
                            https://doi.org/10.1016/s0140-6736(07)60028-2
                        

Identifiers

DOI: 10.1016/s0140-6736(07)60028-2